NMS terminates license agreement with Cardiff Oncology; Cardiff disputes termination

Cardiff Oncology, Inc.

NMS sent termination notice on May 27, 2026, citing alleged material breaches of the 2017 License Agreement.
NMS claims Cardiff failed to correct inventorship to include Dr. Barbara Valsasina on two U.S. patents and failed to use commercially reasonable efforts for onvansertib.
Cardiff filed a lawsuit on May 19, 2026, seeking injunctive relief and declaratory judgment that it did not breach the agreement.
Cardiff responded that the termination notice is legally ineffective and will continue to perform under the agreement.
Dispute centers on rights to onvansertib, a key pipeline asset; potential impact on development timeline.

item 1.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Cardiff Oncology, Inc. terminated License Agreement with Nerviano Medical Sciences S.r.l. (effective 2026-05-27).

Action: termination
Agreement: license
Counterparty: Nerviano Medical Sciences S.r.l.
Effective: 2026-05-27

Exact text from the filing

On May 27, 2026, the Company was informed in writing by NMS that NMS was terminating the Agreement pursuant to Section 11.3 of the Agreement.

View on SEC.gov

Browse all material agreements →

Cardiff Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-248711

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.